health
1 min read
Startup Explores Gene-Editing Technology for Embryos
Origin Genomics, a New York City startup, is conducting research into gene-editing technology for human embryos. The company's work focuses on repairing disease-causing genes and assessing the potential benefits against associated risks.
09/29/2026 · District of Columbia edition
Advertisement
Advertisement
Why it matters locally: While the direct impact on District of Columbia residents is not immediately clear, the ethical and regulatory discussions surrounding embryo gene-editing technology could involve federal oversight bodies and policy debates that impact the District as the nation's capital.
NEW YORK — Origin Genomics, a startup based in New York City, is developing technology designed to edit disease-causing genes within human embryos. The company states its objective is to demonstrate that the potential advantages of its gene-editing method outweigh any associated risks. Cathy Tie, founder and CEO of Origin Genomics, supervises the replenishment of nutrients for cells used in testing the company's technology. Researchers are employing these cells to evaluate the effectiveness of their gene-repairing techniques.Related Topics
Editorial Transparency
AI-Generated · Written by National DeskArticle Ratings
Factual
0.0
Likeable
0.0
Bias
0.0
Objective
0.0
How do you feel about this story?
NA
National Desk
Trust 3.198322 articles8,256,373 views75% fact accuracy
View ProfileSign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!